Abstract
Purpose. To investigate the disposition of valproyl glycinamide and valproyl glycine in rats and to compare it with that of valproic acid (VPA) and valpromide which were studied previously.
Methods. The study was carried out by monitoring the brain and liver levels of valproyl glycinamide and valproyl glycine (as a function of time after iv dosing) in addition to the regular pharmacokinetic (PK) monitoring of plasma and urine levels of these compounds.
Results. The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 1/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h. The ratios of AUCs of valproyl glycinamide of liver to plasma and brain to plasma were 0.70 and 0.66, respectively. The ratios of the AUCs of valproyl glycine of liver to plasma and brain to plasma were 0.19 and 0.02, respectively.
Conclusions. Valproyl glycinamide distributes better in the brain than VPA, a fact which may contribute to its better anticonvulsant activity. Valproyl glycine was barely distributed in the brain, a fact which may explain its lack of anticonvulsant activity. In addition to the liver, the brain was found to be a minor metabolic site of the biotransformation of valproyl glycinamide to valproyl glycine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
S. Hadad and M. Bialer. Pharm. Res. 12:905–910 (1995).
M. Bialer, S. I. Johannessen, H. J. Kupferberg, R. H. Levy, P. Loiseau, and E. Perucca. Epilepsy Res. 25:299–319 (1996).
S. Blotnik, F. Bergman and M. Bialer. Drug Metab. Disposit. 24:560–564 (1996).
M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed. Marcel Dekker, New York, 1982.
L. Z. Benet and R. L. Galeazzi. J. Pharm. Sci. 68:1071–1074 (1979).
K. Yamaoka, T. Nakagawa, and T. Uno. J. Pharmacokinet. Biopharm. 6:547–588 (1978).
K. Yamaoka. Methods for Pharmacokinetic Analysis for Personal Computer, 2nd ed. p. 145–175. Nako-D, Tokyo, 1986.
S. A. Kaplan, M. L. Jack, S. Cotler, and K. Alexander. J. Pharmacokinet. Biopharm. 1:201–216 (1973).
G. R. Wilkinson and D. G. Shand. Clin. Pharmaco. Ther. 18:377–389 (1975).
M. Rowland and T. Tozer. Clinical Pharmacokinetics. 3rd ed. pp. 158–163. Williams & Wilkins, Baltimore, 1995.
P. L. Altman and D. S. Dittmer. Biological Data Book, 2nd ed. Vol. 3, pp. 1702–1710. Federation of American Societies for Experimental Biology, Bethesda, MD, 1974.
J. Roba, R. Cavalier, A. Cordi, H. Gorisson, M. Herin, P. Janssen de Verbecke, C. Onkelinx, M. Remacle, and W. van Doisser. In New Anticonvulsant Drugs. B. S. Meldrum and R. J. Porter (eds). John Libby, London (1986) pp. 179–190.
O. Abu Salach, S. Hadad, A. Haj-Yehia, S. Sussan, and M. Bialer. Pharm. Res. 11:1429–1434 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blotnik, S., Bergman, F. & Bialer, M. The Disposition of Valproyl Glycinamide and Valproyl Glycine in Rats. Pharm Res 14, 873–878 (1997). https://doi.org/10.1023/A:1012143631873
Issue Date:
DOI: https://doi.org/10.1023/A:1012143631873